Breast Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Breast Cancer, including details on symptoms, genetics, screening, treatment, information.

Volume 2 (2005), Issue 8 (August)

1. Breast cancer metastasis: markers and models.
   Nat Rev Cancer, 5(8): 591-602. [Abstract] [Full-text]
2. DAPI fluorescence in nuclei isolated from tumors.
   J Histochem Cytochem, 53(8): 1033-6. [Abstract] [Full-text]
3. What survival benefits do premenopausal patients with early breast cancer need to make endocrine therapy worthwhile?
   Lancet Oncol, 6(8): 581-8. [Abstract] [Full-text]
4. Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: prospective cohort study of about 300,000 women in US SEER cancer registries.
   Lancet Oncol, 6(8): 557-65. [Abstract] [Full-text]
5. Cyclin E as a prognostic and predictive marker in breast cancer.
   Semin Cancer Biol, 15(4): 319-26. [Abstract] [Full-text]
6. Regulation of volume-sensitive Cl- channels in multi-drug resistant MCF7 cells.
   Biochem Biophys Res Commun, 334(4): 1266-78. [Abstract] [Full-text]
7. Modulation of epirubicin cytotoxicity by tamoxifen in human breast cancer cell lines.
   Biochem Pharmacol, 70(5): 725-32. [Abstract] [Full-text]
8. Pit-1 is expressed in normal and tumorous human breast and regulates GH secretion and cell proliferation.
   Eur J Endocrinol, 153(2): 335-44. [Abstract] [Full-text]
9. It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
   Cancer Res, 65(15): 6957-66. [Abstract] [Full-text]
10. Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
    Cancer Res, 65(15): 6943-9. [Abstract] [Full-text]
11. A bifunctional targeted peptide that blocks HER-2 tyrosine kinase and disables mitochondrial function in HER-2-positive carcinoma cells.
    Cancer Res, 65(15): 6891-900. [Abstract] [Full-text]
12. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Cancer Res, 65(15): 6801-10. [Abstract] [Full-text]
13. CD44 attenuates metastatic invasion during breast cancer progression.
    Cancer Res, 65(15): 6755-63. [Abstract] [Full-text]
14. Cellular mechanisms for low-dose ionizing radiation-induced perturbation of the breast tissue microenvironment.
    Cancer Res, 65(15): 6734-44. [Abstract] [Full-text]
15. A Ras homologue member I directly inhibits signal transducers and activators of transcription 3 translocation and activity in human breast and ovarian cancer cells.
    Cancer Res, 65(15): 6701-10. [Abstract] [Full-text]
16. Mechanism of cell cycle regulation by FIP200 in human breast cancer cells.
    Cancer Res, 65(15): 6676-84. [Abstract] [Full-text]
17. PED mediates AKT-dependent chemoresistance in human breast cancer cells.
    Cancer Res, 65(15): 6668-75. [Abstract] [Full-text]
18. High mobility group A2 potentiates genotoxic stress in part through the modulation of basal and DNA damage-dependent phosphatidylinositol 3-kinase-related protein kinase activation.
    Cancer Res, 65(15): 6622-30. [Abstract] [Full-text]
19. CXCL-12/stromal cell-derived factor-1alpha transactivates HER2-neu in breast cancer cells by a novel pathway involving Src kinase activation.
    Cancer Res, 65(15): 6493-7. [Abstract] [Full-text]
20. Allelic association of the human homologue of the mouse modifier Ptprj with breast cancer.
    Hum Mol Genet, 14(16): 2349-56. [Abstract] [Full-text]
21. Effect of exercise training on C-reactive protein in postmenopausal breast cancer survivors: a randomized controlled trial.
    Brain Behav Immun, 19(5): 381-8. [Abstract] [Full-text]
22. HER-2: a biomarker at the crossroads of breast cancer immunotherapy and molecular medicine.
    J Cell Physiol, 205(1): 10-8. [Abstract] [Full-text]
23. American Joint Committee on Cancer tumor-node-metastasis stage after neoadjuvant chemotherapy and breast cancer outcome.
    J Natl Cancer Inst, 97(15): 1137-42. [Abstract] [Full-text]
24. Elevated G2 chromosomal radiosensitivity in Irish breast cancer patients: a comparison with other studies.
    Int J Radiat Biol, 81(5): 373-8. [Abstract] [Full-text]
25. Primary systemic chemotherapy with sequential, dose-dense epirubicin and docetaxel for inoperable, locally advanced inflammatory breast cancer: a phase II study.
    Acta Oncol, 44(3): 248-54. [Abstract] [Full-text]
26. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
    Acta Oncol, 44(3): 240-7. [Abstract] [Full-text]
27. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer.
    Proc Natl Acad Sci U S A, 102(31): 11005-10. [Abstract] [Full-text]
28. Exploiting scale-free information from expression data for cancer classification.
    Comput Biol Chem, 29(4): 288-93. [Abstract] [Full-text]
29. Association of estrogen receptor alpha polymorphisms with breast cancer risk in older Caucasian women.
    Int J Cancer, 116(6): 984-91. [Abstract] [Full-text]
30. Reproductive factors and subtypes of breast cancer defined by hormone receptor and histology.
    Br J Cancer, 93(3): 364-71. [Abstract] [Full-text]
31. Bradykinin stimulates cell proliferation through an extracellular-regulated kinase 1 and 2-dependent mechanism in breast cancer cells in primary culture.
    J Endocrinol, 186(2): 291-301. [Abstract] [Full-text]
32. A systematic review of taxane-containing regimens for metastatic breast cancer.
    Br J Cancer, 93(3): 293-301. [Abstract] [Full-text]
33. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers.
    Br J Cancer, 93(3): 287-92. [Abstract] [Full-text]
34. A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes.
    Oncogene, 24(33): 5235-45. [Abstract] [Full-text]
35. Statistical kinematics of axillary nodal metastases in breast carcinoma.
    Clin Exp Metastasis, 22(2): 177-83. [Abstract] [Full-text]
36. Benzo-[a]-pyrene increases invasion in MDA-MB-231 breast cancer cells via increased COX-II expression and prostaglandin E2 (PGE2) output.
    Clin Exp Metastasis, 22(2): 149-56. [Abstract] [Full-text]
37. Tumour size distribution in mammography screening.
    Breast, 14(4): 329-32. [Abstract] [Full-text]
38. Is complete axillary lymph node dissection neccessary in T1 stage invasive pure tubular carcinomas of the breast?
    Breast, 14(4): 325-8. [Abstract] [Full-text]
39. Intracystic papillary carcinoma of the breast in a male patient diagnosed by core needle biopsy: a case report.
    Breast, 14(4): 322-4. [Abstract] [Full-text]
40. The impact of the physician on the accrual to randomized clinical trials in patients with primary operable breast cancer.
    Breast, 14(4): 310-6. [Abstract] [Full-text]
41. Docetaxel and cisplatin combination chemotherapy in metastatic breast cancer patients with previous exposure to anthracyclines.
    Breast, 14(4): 304-9. [Abstract] [Full-text]
42. Selective use of post-mastectomy flap irradiation in high-risk breast cancer patients.
    Breast, 14(4): 298-303. [Abstract] [Full-text]
43. Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast-a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours.
    Breast, 14(4): 290-7. [Abstract] [Full-text]
44. The Western Australian gestational breast cancer project: a population-based study of the incidence, management and outcomes.
    Breast, 14(4): 276-82. [Abstract] [Full-text]
45. Categorizing breast mammographic density: intra- and interobserver reproducibility of BI-RADS density categories.
    Breast, 14(4): 269-75. [Abstract] [Full-text]
46. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
    Breast, 14(4): 264-8. [Abstract] [Full-text]
47. SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer.
    Breast, 14(4): 250-5. [Abstract] [Full-text]
48. The use of additional imaging increased specificity and decreased sensitivity in screening mammography.
    J Clin Epidemiol, 58(9): 942-50. [Abstract] [Full-text]
49. Searching one or two databases was insufficient for meta-analysis of observational studies.
    J Clin Epidemiol, 58(9): 867-73. [Abstract] [Full-text]
50. The effect of tissue fixation and processing on breast cancer size.
    Hum Pathol, 36(7): 756-60. [Abstract] [Full-text]
51. MR-guided interventions of the breast.
    Magn Reson Imaging Clin N Am, 13(3): 505-17. [Abstract] [Full-text]
52. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Lancet, 366(9484): 455-62. [Abstract] [Full-text]
53. Beyond dichotomies of health and illness: life after breast cancer.
    Nurs Inq, 12(3): 200-9. [Abstract] [Full-text]
54. Quantitative analysis of membrane proteins from breast cancer cell lines BT474 and MCF7 using multistep solid phase mass tagging and 2D LC/MS.
    J Proteome Res, 4(4): 1427-33. [Abstract] [Full-text]
55. The validation of new aromatase monoclonal antibodies for immunohistochemistry--a correlation with biochemical activities in 46 cases of breast cancer.
    J Steroid Biochem Mol Biol, 95(1): 35-9. [Abstract] [Full-text]
56. Adaptive hypersensitivity to estrogen: mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment.
    J Steroid Biochem Mol Biol, 95(1): 155-65. [Abstract] [Full-text]
57. Surgical issues surrounding use of aromatase inhibitors.
    J Steroid Biochem Mol Biol, 95(1): 97-103. [Abstract] [Full-text]
58. Effects of anastrozole on the intratumoral gene expression in locally advanced breast cancer.
    J Steroid Biochem Mol Biol, 95(1): 105-11. [Abstract] [Full-text]
59. Aromatase inhibitors: future directions.
    J Steroid Biochem Mol Biol, 95(1): 183-7. [Abstract] [Full-text]
60. Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes.
    Cancer, 104(4): 700-7. [Abstract] [Full-text]
61. Aromatase inhibitors: cellular and molecular effects.
    J Steroid Biochem Mol Biol, 95(1): 83-9. [Abstract] [Full-text]
62. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance.
    J Steroid Biochem Mol Biol, 95(1): 173-81. [Abstract] [Full-text]
63. Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials.
    J Steroid Biochem Mol Biol, 95(1): 91-5. [Abstract] [Full-text]
64. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma.
    Cancer, 104(4): 682-91. [Abstract] [Full-text]
65. Occult breast lesions: A comparison between radioguided occult lesion localisation (ROLL) vs. wire-guided lumpectomy (WGL).
    Breast, 14(4): 283-9. [Abstract] [Full-text]
66. Mechanisms of resistance to aromatase inhibitors.
    J Steroid Biochem Mol Biol, 95(1): 167-72. [Abstract] [Full-text]
67. Incidence of anaphylactoid reactions to isosulfan blue dye during breast carcinoma lymphatic mapping in patients treated with preoperative prophylaxis: results of a surgical prospective clinical practice protocol.
    Cancer, 104(4): 692-9. [Abstract] [Full-text]
68. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review.
    Cancer, 104(4): 856-63. [Abstract] [Full-text]
69. Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy.
    Cancer, 104(4): 676-81. [Abstract] [Full-text]
70. Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions.
    Cancer, 104(4): 708-18. [Abstract] [Full-text]
71. Model systems: mechanisms involved in the loss of sensitivity to letrozole.
    J Steroid Biochem Mol Biol, 95(1): 41-8. [Abstract] [Full-text]
72. Translational studies on aromatase, cyclooxygenases, and enzyme inhibitors in breast cancer.
    J Steroid Biochem Mol Biol, 95(1): 129-36. [Abstract] [Full-text]
73. Positive and negative transcriptional regulation of aromatase expression in human breast cancer tissue.
    J Steroid Biochem Mol Biol, 95(1): 17-23. [Abstract] [Full-text]
74. Aromatase inhibitors--socio-economical issues.
    J Steroid Biochem Mol Biol, 95(1): 137-42. [Abstract] [Full-text]
75. Aromatase inhibitors for therapy of advanced breast cancer.
    J Steroid Biochem Mol Biol, 95(1): 113-9. [Abstract] [Full-text]
76. Vascular effects of aromatase inhibitors: data from clinical trials.
    J Steroid Biochem Mol Biol, 95(1): 143-9. [Abstract] [Full-text]
77. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.
    J Steroid Biochem Mol Biol, 96(2): 95-108. [Abstract] [Full-text]
78. Growth-related oncogene produced in human breast cancer cells and regulated by Syk protein-tyrosine kinase.
    Int J Cancer, 117(1): 14-20. [Abstract] [Full-text]
79. Effects of screening for breast cancer on its age-incidence relationships and familial risk.
    Int J Cancer, 117(1): 145-9. [Abstract] [Full-text]
80. Serological identification of breast cancer-related antigens from a Saccharomyces cerevisiae surface display library.
    Int J Cancer, 117(1): 104-13. [Abstract] [Full-text]
81. Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates.
    Int J Cancer, 117(1): 150-9. [Abstract] [Full-text]
82. Ethnicity, genetics, and breast cancer: media portrayal of disease identities.
    Ethn Health, 10(3): 185-97. [Abstract] [Full-text]
83. Involvement of HP1alpha protein in irreversible transcriptional inactivation by antiestrogens in breast cancer cells.
    FEBS Lett, 579(20): 4278-86. [Abstract] [Full-text]
84. Secretory carcinoma of the breast. Case report and review of the literature.
    Oncology, 68(2): 263-8. [Abstract] [Full-text]
85. The absence of immunoreactivity for tissue inhibitor of metalloproteinase-1 (TIMP-1), but not for TIMP-2, protein is associated with a favorable prognosis in aggressive breast carcinoma.
    Oncology, 68(2): 196-203. [Abstract] [Full-text]
86. Collision/composite tumors of the adrenal gland: a pitfall of scintigraphy imaging and hormone assays in the detection of adrenal metastasis.
    J Clin Endocrinol Metab, 90(8): 4924-9. [Abstract] [Full-text]
87. Economic evaluation of proton radiation therapy in the treatment of breast cancer.
    Radiother Oncol, 75(2): 179-85. [Abstract] [Full-text]
88. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
    J Clin Oncol, 23(23): 5314-22. [Abstract] [Full-text]
89. Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
    J Clin Oncol, 23(23): 5323-33. [Abstract] [Full-text]
90. Sequencing of aromatase inhibitors.
    Br J Cancer, 93: S6-9. [Abstract] [Full-text]
91. The effects of aromatase inhibitors on lipids and thrombosis.
    Br J Cancer, 93: S23-7. [Abstract] [Full-text]
92. Bone loss and the aromatase inhibitors.
    Br J Cancer, 93: S16-22. [Abstract] [Full-text]
93. Potential use of COX-2-aromatase inhibitor combinations in breast cancer.
    Br J Cancer, 93: S10-5. [Abstract] [Full-text]
94. Role of aromatase inhibitors in breast cancer.
    Br J Cancer, 93: S1-5. [Abstract] [Full-text]
95. A conditional feedback loop regulates Ras activity through EphA2.
    Cancer Cell, 8(2): 111-8. [Abstract] [Full-text]
96. Metastasis gets site specific.
    Cancer Cell, 8(2): 93-5. [Abstract] [Full-text]
97. Influence of psychological response on breast cancer survival: 10-year follow-up of a population-based cohort.
    Eur J Cancer, 41(12): 1710-4. [Abstract] [Full-text]
98. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Eur J Cancer, 41(12): 1678-89. [Abstract] [Full-text]
99. 'Indirect' BRCA1/2 testing: a useful approach in hereditary breast and ovarian cancer families without a living affected relative.
    Clin Genet, 68(3): 228-33. [Abstract] [Full-text]
100. Psychological functioning in African American women at an increased risk of hereditary breast and ovarian cancer.
     Clin Genet, 68(3): 222-7. [Abstract] [Full-text]
101. HRT and breast cancer: impact on population risk and incidence.
     Eur J Cancer, 41(12): 1775-81. [Abstract] [Full-text]
102. Evaluation of potential Stat3-regulated genes in human breast cancer.
     Biochem Biophys Res Commun, 335(2): 292-9. [Abstract] [Full-text]
103. Adjuvant endocrine therapy in postmenopausal women with early breast cancer: where are we now?
     Eur J Cancer, 41(12): 1667-77. [Abstract] [Full-text]
104. Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ.
     Eur J Cancer, 41(12): 1715-23. [Abstract] [Full-text]
105. No increased susceptibility to breast cancer from combined CHEK2 1100delC genotype and the HLA class III region risk factors.
     Eur J Cancer, 41(12): 1819-23. [Abstract] [Full-text]
106. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1.
     J Biol Chem, 280(33): 29625-36. [Abstract] [Full-text]
107. Breast conserving surgery and accelerated partial breast irradiation using the MammoSite system: initial clinical experience.
     Arch Surg, 140(8): 787-94. [Abstract] [Full-text]
108. Phase II study of an 'all-oral' regimen of capecitabine, idarubicin and cyclophosphamide for metastatic breast cancer--safety, efficacy and quality of life.
     Oncology, 68(4): 520-5. [Abstract] [Full-text]
109. Dose-dense sequential adriamycin-Paclitaxel-cyclophosphamide chemotherapy is well tolerated and safe in high-risk early breast cancer.
     Oncology, 68(4): 446-53. [Abstract] [Full-text]
110. Weekly docetaxel and gemcitabine as first-line treatment for metastatic breast cancer: results of a multicenter phase II study.
     Oncology, 68(4): 438-45. [Abstract] [Full-text]
111. Reduced expression of PTEN protein and its prognostic implications in invasive ductal carcinoma of the breast.
     Oncology, 68(4): 398-404. [Abstract] [Full-text]
112. Biweekly docetaxel-irinotecan treatment with filgrastim support is highly active in antracycline-Paclitaxel-refractory breast cancer patients.
     Oncology, 68(4): 391-7. [Abstract] [Full-text]
113. Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer.
     Oncology, 68(4): 364-70. [Abstract] [Full-text]
114. Weekly docetaxel in pretreated metastatic breast cancer patients: a phase I-II study.
     Oncology, 68(4): 356-63. [Abstract] [Full-text]
115. Free fatty acid release from human breast cancer tissue inhibits cytotoxic T-lymphocyte-mediated killing.
     J Lipid Res, 46(9): 1983-90. [Abstract] [Full-text]
116. The role of education in managing fatigue, anxiety, and sleep disorders in women undergoing chemotherapy for breast cancer.
     Appl Nurs Res, 18(3): 138-47. [Abstract] [Full-text]
117. Mortality following development of breast cancer while using oestrogen or oestrogen plus progestin: a computer record-linkage study.
     Br J Cancer, 93(4): 392-8. [Abstract] [Full-text]
118. Role of detection method in predicting breast cancer survival: analysis of randomized screening trials.
     J Natl Cancer Inst, 97(16): 1195-203. [Abstract] [Full-text]
119. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers.
     Am J Surg, 190(3): 371-5. [Abstract] [Full-text]
120. Is breast cancer sentinel lymph node mapping valuable for patients in their seventies and beyond?
     Am J Surg, 190(3): 366-70. [Abstract] [Full-text]
121. Differential effects of estrogen on DNA synthesis in human periodontal ligament and breast cancer cells.
     J Periodontal Res, 40(5): 401-6. [Abstract] [Full-text]
122. Estrogen receptor-alpha regulates SOCS-3 expression in human breast cancer cells.
     Biochem Biophys Res Commun, 335(1): 168-74. [Abstract] [Full-text]
123. Primary chemotherapy with gemcitabine, epirubicin and taxol (GET) in operable breast cancer: a phase II study.
     Br J Cancer, 93(4): 406-11. [Abstract] [Full-text]
124. Growth factors change nuclear distribution of estrogen receptor-alpha via mitogen-activated protein kinase or phosphatidylinositol 3-kinase cascade in a human breast cancer cell line.
     Endocrinology, 146(9): 4082-9. [Abstract] [Full-text]
125. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.
     Mol Cell Biol, 25(17): 7917-25. [Abstract] [Full-text]
126. Trends in the quality of care and racial disparities in Medicare managed care.
     N Engl J Med, 353(7): 692-700. [Abstract] [Full-text]
127. Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.
     J Clin Oncol, 23(24): 5552-9. [Abstract] [Full-text]
128. Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.
     J Clin Oncol, 23(24): 5542-51. [Abstract] [Full-text]
129. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data.
     J Clin Oncol, 23(24): 5534-41. [Abstract] [Full-text]
130. Patient involvement in surgery treatment decisions for breast cancer.
     J Clin Oncol, 23(24): 5526-33. [Abstract] [Full-text]
131. Primary breast lymphoma: outcome of 7 patients and a review of the literature.
     Leuk Lymphoma, 46(9): 1321-7. [Abstract] [Full-text]
132. The 2,5 oligoadenylate synthetase/RNaseL pathway is a novel effector of BRCA1- and interferon-gamma-mediated apoptosis.
     Oncogene, 24(35): 5492-501. [Abstract] [Full-text]
133. The antiapoptotic effect of fibroblast growth factor-2 is mediated through nuclear factor-kappaB activation induced via interaction between Akt and IkappaB kinase-beta in breast cancer cells.
     Oncogene, 24(35): 5482-91. [Abstract] [Full-text]
134. Associations of ErbB2, beta1-integrin and lipid rafts on Herceptin (Trastuzumab) resistant and sensitive tumor cell lines.
     Cancer Lett, 227(2): 201-12. [Abstract] [Full-text]
135. Inhibitory effects of costunolide on the telomerase activity in human breast carcinoma cells.
     Cancer Lett, 227(2): 153-62. [Abstract] [Full-text]
136. The Ataxia-telangiectasia mutated gene and breast cancer: gene expression profiles and sequence variants.
     Cancer Lett, 227(2): 105-14. [Abstract] [Full-text]
137. Hedgehog signaling pathway as a therapeutic target in breast cancer.
     Cancer Lett, 227(2): 99-104. [Abstract] [Full-text]
138. The incidence and functional consequences of RT-associated cardiac perfusion defects.
     Int J Radiat Oncol Biol Phys, 63(1): 214-23. [Abstract] [Full-text]
139. Definition of postlumpectomy tumor bed for radiotherapy boost field planning: CT versus surgical clips.
     Int J Radiat Oncol Biol Phys, 63(1): 209-13. [Abstract] [Full-text]
140. Monoclonal antibody 5C3 raised against formalin fixed paraffin-embedded invasive breast tumour tissue: characterisation of its reactive antigen via immunoprecipitation and internal sequencing.
     J Immunol Methods, 303(1): 53-65. [Abstract] [Full-text]
141. Differences in breast self-examination techniques between Caucasian and African American elderly women.
     J Womens Health (Larchmt), 14(6): 476-84. [Abstract] [Full-text]
142. Meta-analysis of sentinel node imprint cytology in breast cancer.
     Br J Surg, 92(9): 1068-80. [Abstract] [Full-text]
143. Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes.
     Tumour Biol, 26(4): 213-6. [Abstract] [Full-text]
144. Inositol 1,4,5-trisphosphate receptor phosphorylation in breast cancer.
     Tumour Biol, 26(4): 207-12. [Abstract] [Full-text]
145. Tumour-stromal interactions in breast cancer: the role of stroma in tumourigenesis.
     Tumour Biol, 26(4): 173-85. [Abstract] [Full-text]
146. A streamlined platform for high-content functional proteomics of primary human specimens.
     Nat Methods, 2(9): 691-7. [Abstract] [Full-text]
147. Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution.
     Radiology, 236(3): 789-800. [Abstract] [Full-text]
148. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
     Oncology, 69(1): 35-43. [Abstract] [Full-text]
149. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
     Oncology, 69(1): 1-9. [Abstract] [Full-text]
150. Add-on device for stereotactic core-needle breast biopsy: how many biopsy specimens are needed for a reliable diagnosis?
     Radiology, 236(3): 801-9. [Abstract] [Full-text]
151. A pooled analysis of bone marrow micrometastasis in breast cancer.
     N Engl J Med, 353(8): 793-802. [Abstract] [Full-text]
152. The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1.
     Oncogene, 24(36): 5576-88. [Abstract] [Full-text]
153. Recommendations for care related to follow-up of abnormal cancer screening tests: accuracy of patient report.
     Eval Health Prof, 28(3): 310-27. [Abstract] [Full-text]
154. The posterior lymphatic network of the breast rediscovered.
     J Surg Oncol, 91(3): 195-8. [Abstract] [Full-text]
155. Surgical treatment of phyllodes tumors of the breast: retrospective review of 172 cases.
     J Surg Oncol, 91(3): 185-94. [Abstract] [Full-text]
156. Evaluation of breast cancer with a computer-aided detection system by mammographic appearance and histopathology.
     Cancer, 104(5): 931-5. [Abstract] [Full-text]
157. MammoSite excision volume as a predictor for residual disease.
     Cancer, 104(5): 906-12. [Abstract] [Full-text]
158. Axillary recurrence after negative sentinel lymph node biopsy without axillary dissection: a study on 479 breast cancer patients.
     Eur J Surg Oncol, 31(7): 715-20. [Abstract] [Full-text]
159. Early growth response gene 1 (EGR1) is deleted in estrogen receptor-negative human breast carcinoma.
     Cancer, 104(5): 925-30. [Abstract] [Full-text]
160. Continued axillary sampling is unnecessary and provides no further information to sentinel node biopsy in staging breast cancer.
     Eur J Surg Oncol, 31(7): 707-14. [Abstract] [Full-text]
161. Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity.
     Cancer, 104(5): 913-24. [Abstract] [Full-text]
162. Predictors and outcomes of surgeons' referral of older breast cancer patients to medical oncologists.
     Cancer, 104(5): 936-42. [Abstract] [Full-text]
163. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer.
     Int J Cancer, 117(2): 248-55. [Abstract] [Full-text]
164. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene.
     Int J Cancer, 117(2): 230-3. [Abstract] [Full-text]
165. Familial non-BRCA1/BRCA2-associated breast cancer.
     Lancet Oncol, 6(9): 705-11. [Abstract] [Full-text]
166. Management of menopausal symptoms in patients with breast cancer: an evidence-based approach.
     Lancet Oncol, 6(9): 687-95. [Abstract] [Full-text]
167. Identification of molecular markers for metastasis-related genes in primary breast cancer cells.
     Clin Exp Metastasis, 22(1): 59-67. [Abstract] [Full-text]
168. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
     Clin Exp Metastasis, 22(1): 39-46. [Abstract] [Full-text]
169. Correlation of tumor phenotype with c-fms proto-oncogene expression in an in vivo intraperitoneal model for experimental human breast cancer metastasis.
     Clin Exp Metastasis, 22(1): 1-9. [Abstract] [Full-text]
170. Diagnosing breast cancer by using Raman spectroscopy.
     Proc Natl Acad Sci U S A, 102(35): 12371-6. [Abstract] [Full-text]

© 2004-2008 Breast Cancer Research Today. All Rights Reserved.